Sahera Dirajlal-Fargo

Dr. Sahera Dirajlal-Fargo

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in AIDS
Verified
Journal Article
Closed access
SDSahera Dirajlal-Fargo
Sahera Dirajlal-Fargo
MMMarisa M. Mussi-Pinhata
Marisa M. Mussi-Pinhata
AWAdriana Weinberg
Adriana Weinberg
QYQilu Yu
Qilu Yu
RCRachel Cohen
Rachel Cohen
GMGrace A. McComsey
Grace A. McComsey
HIV-exposed uninfected (HEU) infants have increased infectious morbidity and mortality; little is known about their levels of inflammation and monocyte activation. Plasma samples obtained at birth and 6 months from 86 HEU mother-infant pairs enrolled in the NICHD cohorts in Brazil were compared to 88 HIV-unexposed (HU) mother-infant pairs. HIV-infected mothers received antiretroviral therapy during pregnancy, their infants received zidovudine prophylaxis and were not breastfed. IL-6, sTNFR-I and II, sCD14, sCD163, IP-10, VCAM, oxidized LDL, D-Dimer, and hsCRP were assayed by ELISA at birth and at 6 months. sTNF-RI and IL-6 were considered co-primary endpoints. Among HIV-infected mothers, 79% had HIV-RNA <400 copies/mL prior to delivery. Compared to HU, HEU infants had a lower mean gestational age (38.7 vs. 39.3wk) and weight (3.1 vs. 3.3 kg); and reached lower weight (5.9 vs. 8.5 kg) and height (53.6 vs. 68.8 cm) at 6 months. With the exception of VCAM, inflammatory markers were generally higher (p≤0.005) in HEU at birth, but at 6 months only sTNFR-I and IL-6 remained higher. For HEU pairs, only IP-10 was associated with maternal levels at birth (p < 0.001). In HEU, elevated levels of hsCRP and IP10 at birth were associated with lower weight at birth (p = 0.04) and at 6 months (p = 0.04). HIV-exposed infants have heightened inflammation and monocyte activation at birth, which for some markers persisted to 6 months of life and was not related to maternal inflammatory status. Inflammation may contribute to the increased HEU infectious morbidity and poor growth.

1 April 2015 in Antiviral Therapy
Verified
Journal Article
Closed access
SDSahera Dirajlal-Fargo
Sahera Dirajlal-Fargo
AWAllison R Webel
Allison R Webel
CLChris T Longenecker
Chris T Longenecker
BKBruce Kinley
Bruce Kinley
DLDanielle Labbato
Danielle Labbato
GMGrace A McComsey
Grace A McComsey
Background: In HIV-uninfected populations, physical activity decreases mortality and inflammation. Inflammation is a potential cause of comorbidities in HIV+ adults, the evidence examining the effect of physical activity on cardiometabolic health is limited. This analysis examines the relationship between physical activity, cardiometabolic health and inflammation. Methods: We conducted a nested study within the SATURN-HIV trial in which 147 HIV+ adults were randomized to 10 mg daily rosuvastatin or placebo. Measures of physical activity, cardiometabolic health, inflammation and vascular disease (carotid artery intima media thickness and computed tomography-acquired measures pericardial fat volume) were assessed at baseline and through 96 weeks. Spearman correlations and multivariable analyses were used to explore relationships between physical activity, cardiometabolic health and inflammation. Results: Median age (Q1, Q3) was 46 (40.4, 52.7) years, 80% were male, 69% were African American and 46% were on protease inhibitors. Baseline median physical activity was 44 min per week (0, 150), 24% of participants performed greater than 150 min per week. At baseline, physical activity correlated with several markers of cardiometabolic health and inflammation (all P≤0.05). Over all time points median physical activity was independently associated with carotid distensibility (β=2.53; P=0.008), pericardial fat volume (β=-6.13; P=0.001) and interleukin-6 (β=-0.468; P<0.001). Conclusions: Physical activity is associated with vascular disease, endothelial function, and may be an adjuvant to decreasing comorbidities in HIV+ adults. Further studies should examine long-term effects of physical activity on cardiometabolic health and inflammation in this population. Clinicaltrials.gov NCT01218802.

1 May 2016 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SDSahera Dirajlal-Fargo
Sahera Dirajlal-Fargo
CMCarlee Moser
Carlee Moser
TBTodd T. Brown
Todd T. Brown
TKTheodoros Kelesidis
Theodoros Kelesidis
MDMichael P. Dube
Michael P. Dube
GMGrace A. McComsey
Grace A. McComsey
Background. Antiretroviral therapy (ART) can alter glucose metabolism, but little data exist on the association of raltegravir (RAL) with insulin resistance. Methods. A5260s was a substudy of A5257, a prospective open-label randomized trial in which human immunodeficiency virus (HIV)-infected treatment-naive participants were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or RAL over 96 weeks. Baseline and changes in insulin resistance as estimated by the homeostatic model assessment of insulin resistance (HOMA-IR) were assessed. Wilcoxon rank-sum tests were used to assess shifts in the distribution of fold increase from baseline between treatment arms, and Spearman correlation was used to assess associations between HOMA-IR and measures of inflammation and body composition. Results. Three hundred twenty-eight participants were randomized; 90% were male, baseline median age was 36, HIV ribonucleic acid copies were 4.55 log10 copies/mL, and CD4 cell count was 349/mm3. Overall, HOMA-IR increased significantly after 4 weeks (1.9-fold change; 95% confidence interval, 1.73–2.05) then plateaued over the remainder of the study. Changes in HOMA-IR were not different between the arms (P ≥ .23). Changes in HOMA-IR were associated with changes in body mass index at weeks 48 and 96 (r = 0.12–0.22; P ≤ .04). There was a trend with increases in HOMA-IR and increases in visceral abdominal fat at week 96 (r = 0.12; P = .06). At 48 and 96 weeks, HOMA-IR correlated with interleukin-6, high-sensitivity C-reactive protein, and soluble CD163 (r = 0.16–0.27; P ≤ .003). Conclusions. Insulin resistance increased rapidly and then plateaued in treatment-naive participants initiating ART with TDF/FTC, and no differences were found with RAL when compared with ATV/r or DRV/r.

23 May 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SDSahera Dirajlal-Fargo
Sahera Dirajlal-Fargo
VEVanessa El-Kamari
Vanessa El-Kamari
LWLukasz Weiner
Lukasz Weiner
LSLingpeng Shan
Lingpeng Shan
ASAbdus Sattar
Abdus Sattar
GMGrace A McComsey
Grace A McComsey
Children with perinatally acquired human immunodeficiency virus (HIV; PHIVs) face a lifelong cumulative exposure to HIV and antiretroviral therapy (ART). The relationship between gut integrity, microbial translocation, and inflammation in PHIV is poorly understood. This is a cross-sectional study in 57 PHIVs, 59 HIV-exposed but uninfected children, and 56 HIV-unexposed and -uninfected children aged 2–10 years old in Uganda. PHIVs were on stable ART with HIV-1 RNA .05). Among PHIVs who were breastfed, levels of sCD163 and interleukin 6 (IL6) were higher than levels in PHIV who were not breastfed (P < .05). Additionally, in PHIVs with a history of breastfeeding, sCD14, BDG, LBP, zonulin, and I-FABP correlated with several markers of systemic inflammation, including high-sensitivity C-reactive protein, IL6, d-dimer, and systemic tumor necrosis factor receptors I and II (P ≤ .05). Despite viral suppression, PHIVs have evidence of altered gut permeability and fungal translocation. Intestinal damage and the resultant bacterial and fungal translocations in PHIVs may play a role in the persistent inflammation that leads to many end-organ diseases in adults. Despite viral suppression, children with perinatally acquired human immunodeficiency virus (HIV) in Uganda have evidence of alterations in intestinal permeability and fungal translocation, compared to HIV-exposed but uninfected and HIV-unexposed children, which may play a role in HIV-associated chronic inflammation.

3 May 2019 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
LWLukasz D. Weiner
Lukasz D. Weiner
MRMauricio Retuerto
Mauricio Retuerto
CHChristopher L. Hager
Christopher L. Hager
VKVanessa El Kamari
Vanessa El Kamari
LSLingpeng Shan
Lingpeng Shan
GMGrace A. McComsey
Grace A. McComsey
The mechanisms causing HIV-associated immune activation remain incompletely understood. Alteration of intestinal integrity with subsequent translocation of bacterial products appears to play an important role; however, little is known about the impact of fungal translocation. We assessed the effect of fungal translocation and its association with immune activation in people living with HIV (PLWH) compared with uninfected controls. We measured serum levels of β-D-glucan (BDG) and anti- Saccharomyces cerevisiae antibodies (ASCA) immunoglobulin G (IgG) and immunoglobulin A (IgA) and markers of systemic inflammation and immune activation in virally suppressed PLWH on antiretroviral therapy (ART) and uninfected controls. T-test and Mann–Whitney tests were used to compare markers by HIV status and correlation and regression analyses were used to assess associations of fungal translocation markers with markers of inflammation. One hundred seventy-six participants were included (128 HIV+ and 48 HIV−); 72% male, 65% African American, median age was 50 years, and CD4 was 710 cells/cm 3 . Levels of BDG tended to be lower in HIV+ when compared with controls ( p = .05). No significant difference in levels of ASCA IgG and IgA was seen between groups ( p > .75). There was a significant correlation between BDG and several markers of inflammation and immune activation in PLWH, not seen in uninfected controls. In contrast, no correlations were seen between levels of ASCA IgG and IgA with inflammatory markers. PLWH on ART do not have higher levels of BDG or ASCA when compared with uninfected controls, however, the association found between BDG and several inflammation markers suggests a potential role of fungal translocation in the heightened immune activation seen in treated HIV.

10 September 2017 in AIDS
Verified
Journal Article
Closed access
SDSahera Dirajlal-Fargo
Sahera Dirajlal-Fargo
ASAbdus Sattar
Abdus Sattar
MKManjusha Kulkarni
Manjusha Kulkarni
EBEmily Bowman
Emily Bowman
NFNicholas Funderburg
Nicholas Funderburg
GMGrace A McComsey
Grace A McComsey
Objective: Evaluating cardiovascular disease risk in children and youth 13 to 24 years old who are facing a life time exposure to both HIV and antiretroviral therapy is a research priority. This study compares endothelial function measured by peripheral arterial tonometry in HIV-positive youth infected perinatally and behaviorally as well as HIV-negative controls. Methods: Three groups of participants aged 8–30 year were enrolled; HIV-positive perinatally infected, HIV-positive behaviorally infected on antiretroviral therapy with HIV-1 RNA less than 1000 copies/ml, and HIV-negative controls. We measured the reactive hyperemic index, a measure of endothelial function, using endoPAT (Caesarea, Israel). Markers of systemic inflammation, monocyte activation, and gut integrity were also assessed. Spearman correlations and regression analyses were used to explore relationships between endothelial function measures and other measured variables. Results: Overall, 119 participants were enrolled: 53 HIV-positive behaviorally infected, 18 HIV-positive perinatally infected, and 48 controls. Overall, 71% were men; 77% African Americans and median age was 22 years old. Median (interquartile range) reactive hyperemic index was lower in the HIV-positive perinatally infected group [1.34 (1.20, 1.42)], compared with the behaviorally infected group [1.52 (1.34, 1.75)] and the control group [1.52 (1.27, 1.80; P < 0.01)]. Soluble CD14, a marker of monocyte activation, intestinal fatty acid-binding protein, a marker of gut integrity and soluble vascular cell adhesion molecule, a marker of vascular dysfunction, were different among the three groups (P ≤ 0.01). Conclusion: HIV-positive youth infected perinatally appear to have higher levels of endothelial dysfunction and immune activation when compared with behaviorally infected youth. Further longitudinal studies are needed to determine whether perinatally infected youth have higher risks of cardiovascular disease.